Skip to Content
Global News Select

Boston Scientific Buys Surgical Business to Expand Kidney Stone Management Portfolio

By Robb M. Stewart

 

Boston Scientific Corp. struck a deal to buy the global surgical business of privately held Lumenis Ltd. for a $1.07 billion upfront cash payment in a move to expand its kidney stone management portfolio.

The definitive agreement with an affiliate of Baring Private Equity Asia Ltd., which would retain ownership of Lumenis's global aesthetics and ophthalmology businesses, is subject to closing adjustments, Boston Scientific said Wednesday.

The Lumenis surgical business, with 2021 net sales expected to be about $200 million, includes laser systems, fibers and accessories used for urology and otolaryngology procedures, Boston Scientific said.

The medical-technology company has had a relationship with Israel-based Lumenis for more than 20 years and currently sells the Lumenis urology laser portfolio in the U.S. and Japan through a distribution arrangement. After completing the acquisition, Boston Scientific said it would sell the lasers and fibers, as well as the otolaryngology laser portfolio, to all geographies including high-growth regions such as China.

Boston Scientific said it expects to complete the transaction in the second half of the year, with the impact to its adjusted earnings per share forecast to be immaterial in 2021 but is expected to boost EPS by roughly two cents in 2022 and be increasingly accretive thereafter. Due to amortization expense and acquisition-related net charges, it said the purchase is expected to weigh on earnings this year and then be less dilutive or increasingly accretive thereafter.

 

Write to Robb M. Stewart at robb.stewart@wsj.com

 

(END) Dow Jones Newswires

March 03, 2021 07:33 ET (12:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.